Toni K. Choueiri
Broad Institute
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
Renal cell carcinoma treatment
Strong evidence · 17 supporting papers · latest 2026
Cancer Immunotherapy and Biomarkers
Solid evidence · 5 supporting papers · latest 2026
Cancer, Hypoxia, and Metabolism
Solid evidence · 5 supporting papers · latest 2026
Ferroptosis and cancer prognosis
Solid evidence · 6 supporting papers · latest 2026
Prostate Cancer Treatment and Research
Solid evidence · 1 supporting paper · latest 2026
Advanced Breast Cancer Therapies
Solid evidence · 1 supporting paper · latest 2026
Angiogenesis and VEGF in Cancer
Solid evidence · 2 supporting papers · latest 2026
Cancer Research and Treatments
Solid evidence · 2 supporting papers · latest 2026
Publications (18)
72 Time-of-day of Immune Checkpoint Inhibitor Infusion and Overall Survival in Renal Cell Carcinoma: A Real-World Cohort Analysis
2026DOI
66 Relationship Between Health-related Quality of Life and Efficacy in the Phase 3 LITESPARK-005 Study of Belzutifan versus Everolimus in Previously Treated Advanced Clear Cell Renal Cell Carcinoma
2026DOI
49 Effect of Co-Morbidity Burden on the Efficacy and Tolerability of Belzutifan in Patients with Metastatic Renal Cell Carcinoma
2026DOI
61 Differential Pattern of Disease Recurrence in Resected Renal Cell Carcinoma Patients Treated with Adjuvant Pembrolizumab Versus Observation: A Propensity Score-Weighted Analysis
2026DOI
70 Lymphocyte Hsp70 is a Novel Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma
2026DOI
86 SPARCC: A Single Arm Phase 2 Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma (NCT07123090)
2026DOI
6 Antitumor Activity of 177Lu-PSMA-617 in PSMA-Positive Metastatic Clear Cell Renal Cell Carcinoma (ccRCC): Results from a Phase 2 Trial (LASER)
2026DOI
85 Phase 3 LITESPARK-033 (NCT07227402) Study of Belzutifan Plus Zanzalintinib Versus Cabozantinib for Recurrent Clear Cell Renal Cell Carcinoma During or After Adjuvant Anti–PD-(L)1 Therapy
2026DOI
3 Safety Profile of Casdatifan Monotherapy in Patients with Clear Cell Renal Cell Carcinoma: Pooled Analysis of the ARC-20 Study (NCT05536141)
2026DOI
54 Primary Progressive Disease and Outcomes with First-Line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: A Real-World IMDC Analysis
2026DOI
4 Baseline and Early On-Treatment Plasma Kidney Injury Molecule-1 (KIM-1) Levels are Associated with Outcomes in Advanced Renal Cell Carcinoma (aRCC)
2026DOI
74 HIF2α Downregulation and Clinical Outcomes in Patients with Clear Cell Renal Cell Carcinoma with and without Sarcomatoid Differentiation
2026DOI
43 DSG2 and NPNT are Elevated in the Plasma of Metastatic Chromophobe RCC and are Associated with Poorer Overall Survival
2026DOI
19 Dissecting ARNT Expression Patterns in RCC and Association with Outcomes
2026DOI
76 Defining Young-Onset Renal Cell Carcinoma (YORCC): a Registry-Based Analysis of Incidence Trends
2026DOI
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Broad Institute
- Dana-Farber Cancer Institute
Source: OpenAlex · retrieved 2026-09-29
Source: ScienceWe Extractor · retrieved 2026-09-27